Multiple System Atrophy (MSA) Treatment in Delhi, India

Multiple System Atrophy (MSA) is a rare, progressive brain condition. It develops when a protein called alpha-synuclein forms abnormal clumps, known as glial cytoplasmic inclusions, inside specific support cells in the brain. This build-up causes nerve cells in various parts of the brain to break down.

The degeneration of these nerve cells affects several crucial body systems, impacting both movement and the body's involuntary actions, such as blood pressure, digestion, balance, and coordination. MSA is often described as an "atypical parkinsonism" because it shares some features with Parkinson's disease, like slowness and stiffness, but it also leads to more pronounced issues with automatic bodily functions. The condition worsens over time, significantly impacting a person's daily life.

Multiple System Atrophy (MSA) can present in different ways, depending on which parts of the nervous system are most affected. The condition mainly appears in two types: one where symptoms resemble Parkinson’s disease and another where problems with coordination and balance are more noticeable. Here are the two main types.

MSA with Predominant Parkinsonism (MSA-P)

This is the most common type of MSA, especially in Western countries. In MSA-P, the main symptoms are very similar to those seen in Parkinson's disease. The 'P' stands for Parkinsonism.

MSA-P mostly affects movement and individuals with MSA-P primarily experience symptoms such as:

• Slowness of movement (bradykinesia): Actions become much slower and harder to start.
• Stiffness (rigidity): Muscles become rigid, making it difficult to bend or move limbs.
• Balance problems: There can be significant unsteadiness, leading to frequent falls. This is often more severe than in typical Parkinson's.
• Tremor: While some people have a tremor, it is often less noticeable or different from the shaking seen in Parkinson's disease.

Important note: While these symptoms are like Parkinson's, they often do not respond well to the usual Parkinson's medications, or any improvement is very brief.

MSA with Predominant Cerebellar Ataxia (MSA-C)

In this type, the main symptoms relate to problems with coordination and balance. The 'C' stands for Cerebellar, referring to the cerebellum, the part of the brain responsible for coordination. This type is more common in Asian countries.

MSA-P mostly affects Coordination and Balance (Ataxia) and individuals with MSA-P primarily experience symptoms such as:

• Unsteadiness when walking: They might have a wide-legged, clumsy gait and often stumble or fall.
• Difficulty with fine movements: Tasks like writing, buttoning clothes, or picking up small objects become challenging.
• Slurred speech (dysarthria): Speech can become slow, unclear, or sound "drunken."
• Swallowing difficulties (dysphagia): Problems with swallowing food and liquids can occur.
• Eye movement problems: Sometimes there are jerky or uncontrolled eye movements.

Symptoms both types share: Autonomic Dysfunction

No matter which type of MSA someone has, they will also experience problems with their autonomic nervous system. This system controls things our body does automatically without us thinking about them, such as:

• Blood pressure regulation: Especially a severe drop in blood pressure when standing up (called orthostatic hypotension), leading to dizziness or fainting.
• Bladder control: Problems like needing to urinate frequently, urgency, or difficulty emptying the bladder.
• Bowel movements: Often severe constipation.
• Sexual function: For men, erectile dysfunction is often an early symptom.
• Sweating and temperature control: Reduced sweating can make it hard for the body to cool down.
• Sleep problems: Including acting out dreams (REM sleep behaviour disorder) or breathing issues during sleep.

So, while the initial and most obvious symptoms might lean towards either movement stiffness (MSA-P) or coordination problems (MSA-C), severe issues with the body's automatic functions are a key feature that helps doctors identify MSA in all cases.

The exact cause of Multiple System Atrophy (MSA) is currently unknown. It is considered a sporadic condition, meaning it generally occurs at random, without a clear hereditary pattern or specific environmental trigger.

However, research has revealed a key characteristic of MSA that is central to its progression:

• Alpha-Synuclein Accumulation: In individuals with MSA, there is an abnormal build-up of a protein called alpha-synuclein within specific cells of the brain, particularly in oligodendrocytes (support cells for nerve cells). These clumps of protein, known as glial cytoplasmic inclusions, cause damage to nerve cells in crucial areas of the brain, including those responsible for movement, balance, and autonomic functions (like blood pressure, breathing, and digestion). This progressive damage and loss of nerve cells in these regions lead to the wide range of symptoms seen in MSA.

While the fundamental reason for this protein accumulation remains unclear, ongoing research explores various possibilities:

• Genetic Factors: Although MSA is largely sporadic, some studies have investigated potential genetic predispositions or very rare genetic variants that might increase risk in certain populations. However, no single gene has been definitively identified as causing MSA in the majority of cases.
• Environmental Factors: Researchers are also exploring whether exposure to specific environmental toxins or factors could play a role, but there is currently no substantial evidence to support these theories.

While the definitive causes of Multiple System Atrophy are still being researched, certain factors are recognised to be associated with an increased risk of developing the condition. Here are some of the most common risk factors of Multiple System Atrophy

• Age: MSA typically develops in adulthood, with the average age of onset being in the 50s or 60s. It is rarely seen in younger individuals.
• Sex: Some studies suggest a slightly higher prevalence in men than in women, though this difference is not always consistently observed across all research.
• Genetics: As mentioned, while most cases are sporadic, a very small percentage are family-related, indicating that a genetic predisposition can be a minor risk factor in specific families. However, MSA is not considered a hereditary disease in the way many other genetic disorders are.
• Geographical Location: There is no clear geographical pattern, and MSA is found worldwide, suggesting it is not linked to specific regional environmental exposures.

It is crucial to remember that having one or more of these risk factors does not mean an individual will develop MSA. The condition's rarity means that even with potential risk factors, the overall likelihood remains low.

Diagnosing Multiple System Atrophy can be challenging due to its rarity and the overlap of its symptoms with other conditions, particularly Parkinson's disease. At Max Hospitals, our multidisciplinary team is dedicated to providing a precise and timely clinical diagnosis through comprehensive neurological evaluations and advanced diagnostic tests to differentiate MSA from similar conditions and guide effective treatment plans. The diagnostic process typically includes:

Medical History and Physical Examination

A detailed medical history is taken, focusing on the onset and progression of motor and autonomic symptoms. A thorough neurological examination assesses:

• Motor Symptoms: Evaluating for bradykinesia, rigidity, postural instability, tremor, and cerebellar signs like ataxia and dysarthria.
• Autonomic Symptoms: Inquiring about light-headedness on standing, urinary problems, constipation, and sexual dysfunction.
• Other Symptoms: Assessing for sleep disturbances, swallowing difficulties, and any cognitive changes.

Autonomic Function Tests

These tests assess the integrity of the autonomic nervous system:

• Blood Pressure Monitoring: Measuring blood pressure while lying down and then standing to detect orthostatic hypotension.
• Valsalva Manoeuvre: A test that assesses heart rate and blood pressure responses to forced exhalation against a closed airway, which can reveal autonomic dysfunction.
• Quantitative Sudomotor Axon Reflex Test (QSART): Measures the volume of sweat produced in response to a small electrical stimulus, assessing the function of sweat glands and nerves.
• Urodynamic Studies: Tests that evaluate bladder function and the cause of urinary symptoms.

Laboratory Tests

Blood tests are primarily used to rule out other conditions that might present with similar symptoms, such as vitamin deficiencies or other neurological disorders.

• Blood Tests: To check for other causes of neurological symptoms or autonomic dysfunction.

Neuroimaging

While no single imaging test can definitively diagnose MSA, MRI scans of the brain can help support a diagnosis by showing characteristic changes:

• MRI Brain Scans: May reveal atrophy (shrinkage) in specific brain regions, such as the cerebellum, pons, and putamen. Certain MRI sequences, like T2-weighted images, may show characteristic changes in the putamen (e.g., "slit-like" signal changes) or a "hot cross bun" sign in the pons, which are suggestive of MSA but not universally present.
• Dopamine Transporter Scan (DaTscan): This scan is often normal in MSA, unlike in Parkinson's disease where it is typically abnormal. This can help differentiate MSA from Parkinson's disease, particularly in early stages.

Currently, there is no cure for Multiple System Atrophy (MSA), nor are there treatments that can halt or reverse the progression of the disease. Consequently, the primary aim of treatment for MSA is symptomatic and supportive. This means focusing on managing the various symptoms, improving quality of life, and addressing any complications that may arise. At Max Hospitals, we have a multidisciplinary team of specialists dedicated to providing a comprehensive and coordinated treatment approach that includes one or more of the following:. 

Pharmacological Management (Medications)

Medications are prescribed to help alleviate specific symptoms, although their effectiveness can vary from person to person and often diminishes as the disease progresses.

• For Low Blood Pressure (Orthostatic Hypotension): This is a common and often debilitating symptom. Medications such as midodrine or droxidopa may be prescribed to help raise blood pressure by constricting blood vessels. Fludrocortisone might also be used to help the body retain salt and water, thereby increasing blood volume. Alongside medication, non-pharmacological strategies are essential, including increasing salt and fluid intake, wearing compression stockings, and avoiding sudden changes in position.
• For Parkinsonian Symptoms (MSA-P type): For individuals with the MSA-P subtype, levodopa (a common Parkinson's medication) is often trialled. However, any benefit is usually modest and short-lived compared to its effects in Parkinson's disease. Other Parkinson's medications are generally less effective.
• For Bladder Problems: Medications can help manage issues like frequent urination, urgency, or difficulty emptying the bladder. For urinary retention, intermittent or indwelling catheterisation may become necessary.
• For Constipation: Laxatives and stool softeners are commonly used to manage chronic constipation. Dietary adjustments, such as increasing fibre and fluid intake, are also encouraged.
• For Muscle Stiffness and Spasms: Muscle relaxants, such as baclofen, can help reduce rigidity and uncomfortable muscle spasms.
• For Sleep Disorders: Medications like clonazepam may be used to help manage REM sleep behaviour disorder (where individuals act out their dreams). Continuous Positive Airway Pressure (CPAP) may be recommended for sleep apnoea.

Non-Pharmacological and Supportive Therapies

These therapies are fundamental to helping individuals maintain their independence and quality of life for as long as possible.

• Physiotherapy: Regular physiotherapy is essential. It helps to maintain mobility, improve balance, reduce stiffness, and prevent muscles from weakening and joints from stiffening. Physiotherapists can teach specific exercises and strategies to improve gait and reduce the risk of falls.
• Occupational Therapy: Occupational therapists assist individuals in adapting to daily tasks as symptoms progress. They can recommend adaptive equipment (e.g., aids for dressing, eating, or bathing) and techniques to make everyday activities easier and maintain independence.
• Speech and Language Therapy (SALT): SALT addresses difficulties with speech (dysarthria) and swallowing (dysphagia). Therapists can provide exercises to improve vocal clarity and teach strategies for safer swallowing, which may include recommending modified food textures or thickened liquids to prevent aspiration (food or liquid entering the lungs).
• Dietary and Nutritional Support: A dietitian can offer tailored advice to ensure individuals maintain adequate nutrition, especially when swallowing becomes challenging. They can recommend nutrient-rich foods that are easier to consume and monitor for signs of malnutrition or dehydration.
• Psychological Support: Living with a progressive condition like MSA can be emotionally challenging. Counselling, psychological therapies, and support groups can provide invaluable emotional support and coping strategies for individuals with MSA and their families.
• Respiratory Support: As MSA can affect breathing, particularly during sleep, respiratory specialists may be involved. Non-invasive ventilation (e.g., CPAP) might be used, and in advanced stages, interventions like a tracheostomy may be considered for airway management.

Palliative Care

Early involvement of palliative care services is highly recommended for individuals with MSA. Palliative care focuses on providing relief from the symptoms and stress of a serious illness. Its goal is to improve the quality of life for both the patient and their family, addressing not only physical symptoms but also psychological, social, and spiritual needs. Palliative care can be provided alongside other treatments at any stage of the disease.

Multiple System Atrophy is a progressive condition, and as it advances, individuals may experience a range of complications that significantly impact their health and quality of life. These complications arise from the widespread degeneration of nerve cells in both the central and autonomic nervous systems.

Key complications include:

• Severe Orthostatic Hypotension: This can lead to frequent fainting, falls, and injuries, significantly limiting mobility and increasing the risk of hospitalisation.
• Recurrent Falls: Due to severe postural instability and ataxia, falls are common and can result in fractures, head injuries, and further loss of independence.
• Swallowing Difficulties (Dysphagia): As the muscles involved in swallowing weaken, there is a high risk of aspiration pneumonia, where food or liquid enters the lungs. This is a leading cause of morbidity and mortality in MSA.
• Respiratory Dysfunction:
• Stridor: A high-pitched breathing sound, particularly during sleep, due to vocal cord dysfunction. This can lead to respiratory distress and may require a tracheostomy in severe cases.
• Sleep Apnoea: Disordered breathing during sleep.
• Recurrent Chest Infections: Due to aspiration or general weakness.
• Urinary Tract Infections (UTIs): Chronic urinary retention or incontinence can increase the risk of recurrent UTIs.
• Severe Constipation: Can lead to discomfort, impaction, and other gastrointestinal issues.
• Mobility Impairment: Progressive motor symptoms eventually lead to significant disability, often requiring the use of walking aids, wheelchairs, and ultimately, bed confinement.
• Speech Impairment (Dysarthria): Severe speech problems can significantly impair communication, leading to frustration and isolation.
• Nutritional Deficiencies and Weight Loss: Due to difficulties with swallowing and decreased appetite, individuals may struggle to maintain adequate nutrition.
• Psychological Issues: Depression, anxiety, and apathy are common, stemming from the challenges of living with a debilitating and progressive illness.
• Autonomic Crises: In some cases, individuals can experience severe and rapid fluctuations in blood pressure, heart rate, or body temperature.

Managing these complications effectively is a central part of MSA care, aiming to alleviate suffering and preserve as much function and comfort as possible as the disease progresses.

Currently, there are no known measures to prevent Multiple System Atrophy, as the exact cause of the condition remains unclear. However, early recognition of symptoms, timely diagnosis, and structured management can support individuals in maintaining independence and enhancing quality of life. Regular monitoring by a neurologist, adherence to therapy plans, and ongoing adjustments to treatment based on symptom progression can help in managing the impact of the condition effectively. At Max Hospitals, we follow a proactive approach to support individuals and families in addressing the challenges of MSA, focusing on safety, comfort, and overall well-being.

Can MSA affect cognitive function?

While MSA is primarily known for motor and autonomic symptoms, some individuals may experience mild cognitive impairment, particularly affecting executive functions like planning and problem-solving. Severe dementia is less common in MSA compared to some other neurodegenerative conditions.

Is MSA a genetic disease?

The vast majority of MSA cases are sporadic, meaning they do not run in families. Very rare familial cases have been reported, suggesting a genetic predisposition in a small number of individuals. It is, therefore, not considered a hereditary disease.

Are Shy-Drager syndrome, OPCA, and striatonigral degeneration different conditions? 

These conditions were previously described separately but are now understood as different presentations within Multiple System Atrophy, affecting various parts of the nervous system and producing differing symptom patterns.

Is Shy-Drager syndrome the same as Multiple System Atrophy? 

Shy-Drager syndrome is now considered part of Multiple System Atrophy, particularly associated with significant autonomic dysfunction alongside parkinsonian or cerebellar symptoms.

What is the relationship between Multiple System Atrophy and olivopontocerebellar atrophy (OPCA)? 

OPCA refers to the degeneration of the cerebellum, pons, and medulla, leading to balance and coordination difficulties. It is now considered part of the cerebellar subtype of MSA (MSA-C).

How is striatonigral degeneration related to Multiple System Atrophy? 

Striatonigral degeneration involves degeneration of the striatum and substantia nigra, leading to parkinsonian symptoms. It is considered part of the parkinsonian subtype of MSA (MSA-P).

How does MSA differ from Parkinson's disease?

MSA shares some motor symptoms with Parkinson's disease, but it progresses more rapidly and often presents with more severe and earlier onset of autonomic dysfunction (e.g., severe orthostatic hypotension, urinary incontinence). Response to levodopa is also typically poor or short-lived in MSA, unlike in Parkinson's. Additionally, some forms of MSA include prominent cerebellar ataxia, which is not characteristic of typical Parkinson's disease.

What is the average life expectancy after an MSA diagnosis?

MSA is a progressive disease. The average life expectancy from diagnosis typically ranges from 6 to 10 years, though there is significant variability among individuals. 

Are there support groups available for individuals with MSA and their families?

Yes, numerous national and international organisations offer support, resources, and information for individuals with MSA and their caregivers. These groups can provide invaluable emotional support, practical advice, and connections with others facing similar challenges.

Reviewed by Dr. Sanjay Kumar Mishra, Director, Neurosurgery, Neurology, on 21 August 2025.